Romaco Group Announces Finalization of Innojet Acquisition
PTSM: Pharmaceutical Technology Sourcing and Management
Romaco Group announced that it had finished the acquisition of Innojet Herbert Hüttlin, a German company specializing in coating and granulation.
On Feb. 12, 2015, the processing and packaging company Romaco Group announced that it acquired Innojet Herbert Hüttlin, a German company that develops; designs; and produces systems for coating and granulating solids, and functional components for processing tablets, pellets, and powders. Under the agreement, Innojet will become a wholly-owned company of the Romaco Group with the new name Romaco Innojet GmbH. Paulo Alexandre, CEO of Romaco, and Carsten Strenger, COO and CFO of Romaco, and Dr. h.c. Herbert Hüttlin, founder and vendor of Innojet Herbert Hüttlin, will share the management responsibility.
This acquisition will expand Romaco's portfolio to include a range of granulation, tableting, coating, and primary, secondary, and final packaging. Innojet will benefit from Romaco’s global reach, “Innojet will be able to extend its international reach enormously as a result of its integration in Romaco’s worldwide network of sales partners and agents. As an equal entity within the Romaco organisation, Innojet will be optimally placed to leverage the full, unique potential of its technologies,” said Dr. h.c. Herbert Hüttlin, in a press release.
Source: Romaco
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
